bsg healthcare
LabBench Today                                                         October No.1






Like us on Facebook


Follow us on Twitter


View our profile on LinkedIn



Biotech Support Group
1 Deer Park Drive, Suite M
Monmouth JCT, New Jersey 08852
Tel:732-274-2866, 1-800-935-0628
Fax: 732-274-2899


Cleanascite™ lipid removal and clarification reagent for Alzheimer's disease research


Mcintyre, John A. United States Patent: 20120107841. Serum Diagnostic Method, Biomarker and Kit for Early Detection and Staging of Alzheimer's Disease 

United States Patent Application 20120107841 titled, "Serum Diagnostic Method, Biomarker and Kit for Early Detection and Staging of Alzheimer's Disease" cites Cleanascite™ from Biotech Support Group for lipid clarification. Cleanascite™ is used in this patent to remove lipids from serum samples. This patent describes a blood test which measures redox reactive autoantibodies before and after exposure to an oxidative agent in serum for the presence of an elevated level of redox-reactive autoantibodies for developing a laboratory method to screen, diagnose, monitor and/or stage early onset Alzheimer's disease.

Moreover, the patent describes the search for serological biomarkers of Alzheimer's disease (AD) by studying redox-reactive autoantibodies (R-RAA) present in serum which unmask antigen recognition sites upon oxidative exposure. The autoantibodies are detected in blood with an oxidizing agent and using a screening assay to detect antibodies that bind a self antigen. Hemin is the oxidizing agent used for R-RAA aPE ELISA. 

Inventor John Mcintyre developed technology to 'unmask' autoantibodies in serum samples in vitro and matched AD specific epitopes to reactive autoantibodies. The increase in R-RAA aPE in MCI serum samples and changes in hippocampal choline acetyltransferase (ChAT) in end-stage AD or MCI are being exploited as potential biomarkers. Using ELISA to quantitatively measure concentration of unmasked antibodies in serum samples in vitro by the presence of their recognition epitopes, the increase in R-RAA over their base line values and comparison to the increased ELISA reactivity in AD and/or normal individuals is determined. Comparisons between the AD and normal populations revealed highly significant differences in R-RAA antiphosphatidylethanolamine (aPE).



Characteristics of Cleanascite™:

  • A high binding capacity for lipids with minimal cross-reactivity with proteins
  • Effectively replaces chlorinated/fluorinated hydrocarbons (eg. freon) and it is environmentally friendly.
  • Helps purify antibodies, recombinant proteins, nucleic acids, proteoglycans
  • Clarifies saliva and fecal components
  • Very low protein binding
  • Does not bind to DNA, RNA, enzymes and proteins
  • Leaves glycoproteins, antibodies, nucleic acids, hemoglobin, proteoglycans, nucleic acids, serum components(such as hormones, nutrients, globulins, clotting factors, transport proteins) alone
  • Extends the life of membrane and chromatographic columns.
  • Enrichment of delipidated tissue samples
  • Ideal for delipidation treatments for downstream processing of large-scale therapeutic proteins, enzymes and monclonal antibodies. 


Cleanascite™ is an ideal sample clarification and purification reagent for physicochemical fractionation antibody purification, class-specific affinity purification of antibodies, antigen-specific affinity purification of antibodies. It is compatible with large scale antibody purification protocols. During the development process of anti-immunoglobulin E (IgE) antibodies, Cleanascite™ is required because it is a solid phase, non-ionic adsorbent and this specialty technology makes it great for initial purification. It complements other purification biotechniques such as gel filtration, dialysis, ammonium sulfate precipitation or ion exchange chromatography or hydrophobic interaction.



Biotech Support Group | 1 Deer Park Drive, Suite M | Monmouth JCT | NJ | 08852